India is coming soon, they will update us before end of month regarding them in my opinion. I believe the Chinese FDA update will be included in that as well. Right now I believe they’re trying to raise financing for the study which will probably cost a couple million dollars. And this is the bottom, I believe the outstanding shares is just over 20 million. One thing I can tell you is that gene Cartwright hasn’t taking a salary in two years, so I know the financing isn’t to pay the CEOs and higher ups. It’s very clear they are not diluting or at least trying to not over dilute the share pool. I didn’t think they would release a PR during a holiday week so I expect a PR next week for sure and they will update us on all the new developments including India which would be massive. What I also know is the FDA has reduced its requirements for approval of this particular type of device, the data that we do have from the first studies is sufficient for approval I think it’s somewhere around 40% efficacy but I can guarantee you the FDA wants new data which is why we need to build up financing.